Your browser doesn't support javascript.
loading
Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.
Tao, Yunxia; Ge, Gaoran; Wang, Qing; Wang, Wei; Zhang, Wenhao; Bai, Jiaxiang; Lin, Jiayi; Shen, Jining; Guo, Xiaobin; Xu, Yaozeng; Geng, Dechun.
Affiliation
  • Tao Y; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Ge G; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Wang Q; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Wang W; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Zhang W; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Bai J; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Lin J; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Shen J; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Guo X; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Xu Y; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
  • Geng D; Department of Orthopedics, The first Affiliated Hospital of Soochow University, Suzhou, China.
IUBMB Life ; 71(7): 969-977, 2019 07.
Article in En | MEDLINE | ID: mdl-30897288
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology characterized by degradation of cartilage and bone, accompanied by unimpeded proliferation of synoviocytes of altered phenotype. In the present study, we investigated the involvement of the glucagon-like peptide 1 (GLP-1) receptor on human fibroblast-like synoviocytes (FLS) in the pathogenesis of RA using the selective GLP-1 agonist exenatide, a licensed drug used for the treatment of type 2 diabetes. Our results indicate that exenatide may play a role in regulating tumor necrosis factor-α-induced mitochondrial dysfunction by increasing mitochondrial membrane potential, oxidative stress by reducing the production of reactive oxygen species, the expression of NADPH oxidase 4, expression of matrix metalloproteinase (MMP)-3 and MMP-13, release of proinflammatory cytokines including interleukin-1ß (IL-1ß), IL-6, monocyte chemoattractant protein-1, and high-mobility group protein 1, as well as activation of the p38/nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α/nuclear factor κB signaling pathway in primary human RA FLS. These positive results indicate that exenatide may have potential as a therapeutic agent for the treatment and prevention of RA. © 2019 IUBMB Life, 9999(9999):1-9, 2019.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Inflammation Mediators / Fibroblasts / Synoviocytes / Exenatide / Hypoglycemic Agents / Inflammation Limits: Humans Language: En Journal: IUBMB Life Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2019 Type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Inflammation Mediators / Fibroblasts / Synoviocytes / Exenatide / Hypoglycemic Agents / Inflammation Limits: Humans Language: En Journal: IUBMB Life Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2019 Type: Article Affiliation country: China